Koike K, Moore E E, Moore F A, Kim F J, Carl V S, Banerjee A
Department of Surgery, Denver General Hospital, Colorado.
Am J Physiol. 1995 Mar;268(3 Pt 1):G397-403. doi: 10.1152/ajpgi.1995.268.3.G397.
Intestinal ischemia-reperfusion (I/R) provokes polymorphonuclear neutrophil (PMN)-mediated lung injury via a process characterized by circulating PMN priming, pulmonary PMN sequestration, and increased microvascular leak in the lung. We found in rats subjected to intestinal I/R (ischemia 45 min and reperfusion 6 h) that 1) intestinal phospholipase A2 (PLA2) was activated during ischemia, 2) circulating PMN priming (assessed by superoxide production with N-formyl-Met-Leu-Phe) occurred after 1 h reperfusion, and 3) exaggerated 125I-labeled albumin lung leak occurred after 2 h reperfusion, compared with sham-treated animals (P < 0.05). Treatment with a PLA2 inhibitor, quinacrine, within 15 min of reperfusion reversed the exaggerated gut PLA2 activity and abrogated subsequent PMN priming and lung leak (P < 0.05). However, when quinacrine was administered after 2 h of reperfusion, circulating PMN priming and lung leak continued to evolve despite suppression of intestinal PLA2 activity. We conclude that intestinal PLA2 activation may be a prerequisite for the sequelae of circulating PMN priming and pulmonary microvascular leak observed after intestinal I/R.
肠道缺血再灌注(I/R)通过一个以循环中性粒细胞预激活、肺部中性粒细胞滞留以及肺部微血管通透性增加为特征的过程,引发多形核中性粒细胞(PMN)介导的肺损伤。我们在经历肠道I/R(缺血45分钟和再灌注6小时)的大鼠中发现:1)肠道磷脂酶A2(PLA2)在缺血期间被激活;2)再灌注1小时后出现循环PMN预激活(通过用N-甲酰甲硫氨酰亮氨酰苯丙氨酸刺激产生超氧化物来评估);3)与假手术处理的动物相比,再灌注2小时后125I标记的白蛋白肺部渗漏加剧(P<0.05)。在再灌注15分钟内用PLA2抑制剂奎纳克林进行治疗,可逆转肠道PLA2活性的过度升高,并消除随后的PMN预激活和肺部渗漏(P<0.05)。然而,当在再灌注2小时后给予奎纳克林时,尽管肠道PLA2活性受到抑制,但循环PMN预激活和肺部渗漏仍继续发展。我们得出结论,肠道PLA2激活可能是肠道I/R后观察到的循环PMN预激活和肺微血管渗漏后遗症的一个先决条件。